My thoughts are that some smaller speculative funds may find 008 success enough to buy-in, plus those in the cap raise will add, however little value for FDA. Retailers who are already in a world of pain will only use it as an opportunity to exit. Competition is a worry. I'd back Novartis over PR and DS, at least from an organisational perspective. Much bigger company, more resources.
Ann: Investor Presentation - $66m Capital Raise, page-62
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
-0.005(2.38%) |
Mkt cap ! $71.73M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 21.0¢ | 20.0¢ | $152.8K | 744.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 78174 | 20.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 84426 | 5 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |